Eledon reports positive Phase 2a topline results for tegoprubart in ALS patients

Eledon Pharmaceuticals, Inc.

Tegoprubart met primary safety and tolerability endpoints; no drug-related serious adverse events observed.
Dose-dependent target engagement at 4 and 8 mg/kg; anti-drug antibodies in <5% of samples, low titer.
Pro-inflammatory ALS signature of 32 biomarkers identified; dose-dependent reduction in up to 23 biomarkers.
Trend in slowing ALS progression (ALSFRS slope) vs. PRO-ACT database; study not powered for efficacy.
Reduced biomarkers also associated with IgA nephropathy and kidney transplant rejection (IgA, C3, CXCL9, etc.).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.